Chabiotech Co

Chabiotech Co FCF Yield

The Free Cash Flow Yield of Chabiotech Co (085660.KQ) as of Nov 1, 2026 is -12.22 %. In the previous year, Free Cash Flow Yield was -8.06 % — a change of 51.70% (lower).

FCF Yield

-12.22 %

YoY

51.70%

Last updated:

Free Cash Flow Yield of Chabiotech Co is 2025 -12.22 % . Free Cash Flow Yield of Chabiotech Co was 2024 -8.06 % . It decreases by 51.70% lower compared to the previous year.

The Chabiotech Co FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
-0.15 KRW
Jan 1, 2019
-4.49 KRW
Jan 1, 2020
-4.31 KRW
Jan 1, 2021
-5.07 KRW
Jan 1, 2022
-8.13 KRW
Jan 1, 2023
-3.42 KRW
Jan 1, 2024
-8.06 KRW
Jan 1, 2025
-12.22 KRW
The Chabiotech Co FCF Yield history
YEARFCF YieldYoY
-12.22 %+51.70%
-8.06 %+135.51%
-3.42 %-57.95%
-8.13 %+60.37%
-5.07 %+17.66%
-4.31 %-4.00%
-4.49 %+2,894.50%
-0.15 %-88.93%
-1.35 %+9.06%
-1.24 %-174.85%
1.66 %-163.81%
-2.60 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Chabiotech Co Stock analysis

What does Chabiotech Co do? Cha Biotech Co., Ltd. generates revenue through its bio segment, which provides medical services, develops stem cell and cell therapy products, produces cosmetics and cosmetic raw materials, distributes medical devices, and offers cord blood storage and health care services. The optical segment manufactures optical lenses, optical modules, and other parts for mobile phone cameras. The company serves healthcare providers, medical device distributors, and consumers seeking cosmetic and health services. Its bio segment targets medical and wellness markets, while the optical segment caters to mobile phone manufacturers and component suppliers. The company's products include stem cell therapy solutions, cosmetic raw materials, medical devices, and optical components. It operates through two main segments: bio and optical, with the bio segment focusing on healthcare and wellness services, and the optical segment on manufacturing optical parts for mobile devices. The bio segment's cord blood storage services are a key offering for health-conscious consumers, while the optical segment supplies components to mobile phone camera manufacturers. Cha Biotech's revenue streams come from medical service provision, product development in cell therapy, cosmetic production, medical device distribution, cord blood storage, and optical component manufacturing. The company serves healthcare institutions, cosmetic brands, medical device companies, and mobile phone manufacturers. Its bio segment's health care services and optical segment's mobile phone camera parts are central to its business model. Chabiotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Chabiotech Co stock

Free Cash Flow Yield of Chabiotech Co is -12.22 % in 2025.

Free Cash Flow Yield of Chabiotech Co changed from -8.06 % to -12.22 %, representing a 51.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Chabiotech Co since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Chabiotech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Chabiotech Co

All Key Metrics — Chabiotech Co